|
Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research |
PA-18-902 (R01 Clinical Trial Optional) |
09/08/2021 |
|
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention |
PAR-19-252 (R21 Clinical Trial Optional) |
11/09/2021 |
|
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention |
PAR-19-251 (R01 Clinical Trial Optional) |
11/09/2021 |
|
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research |
PAR-19-113 (R01 Clinical Trial Optional) |
01/08/2022 |
|
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer |
PAR-19-264 (R01 Clinical Trial Optional) |
12/11/2021 |
|
Notice of Correction to Application Types Allowed for PAR-20-053, Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection |
NOT-CA-20-067 (R01 Clinical Trial Not Allowed) |
01/08/2023 |
|
Notice of Special Interest (NOSI): Advancing Head and Neck Cancer Early Detection Research (AHEAD) |
NOT-CA-20-031 |
01/08/2022 |
|
Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions |
NOT-CA-20-044 |
05/08/2023 |
|
Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine |
PAR-18-841 (U24 - Clinical Trial Optional) |
06/15/2021 |
|
Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection |
PAR-20-053 (R01 Clinical Trial Not Allowed) |
01/08/2023 |
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes |
PAR-20-276 (R01 Clinical Trial Not Allowed) |
09/08/2022 |
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes |
PAR-20-277 (R21 Clinical Trials Not Allowed) |
09/08/2022 |
